ClinicaliQ Trial Snapshot
- Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V — Recruiting • Phase II • Rheumatology • NCT05268289.
- What is being tested: Iptacopan (LNP023), a complement factor B inhibitor, is being evaluated as an add-on therapy to standard care in patients with active lupus nephritis (Classes III-IV, +/- V), assessing its efficacy, safety and tolerability through a two-part study design.
- Patient eligibility overview: The trial enrolls participants with biopsy-confirmed active lupus nephritis, specifically Classes III-IV with or without Class V involvement, who are receiving concurrent standard of care immunosuppressive treatment.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Eligibility Snapshot
- : Unequivocally positive ANA test result and/or a positive anti dsDNA at screening Active biopsy-proven lupus nephritis within 3 months of screening demonstrating Class III or IV lupus nephritis with or without co-existing features of Class V lupus nephritis. Documentation of active renal disease at the time of screening necessitating the commencement of therapy with corticosteroids in combination with MMF/MPS. eGFR ≥ 30 ml/min/1.73 m2 Vaccination against Neisseria meningitidis and Streptococcus pneumoniae infections Vaccination against Haemophilus influenzae infection Supportive care including stable dose regimen of anti-malarials (e.g. hydroxychloroquine) unless contraindicated, ACEi or ARB at either locally approved maximal daily dose or the maximally tolerated dose (per investigators' judgement) at screening, as per the local clinical practice. Doses should remain stable throughout the study. First presentation or flare of lupus nephritis.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.